A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer

drug protocol number
I3Y-MC-JPCF
drug sponsor
Eli Lilly
drug study
abemaciclib
drug trial site
KFMC
drug status
Ongoing
drug phase